Tonix Pharmaceuticals shares are trading higher after the company announced receipt of the formal minutes from a recent pre-New Drug Application Type-B Chemistry, Manufacturing, and Controls meeting with the FDA for Tonmya for the management of fibromyalgia.
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals shares are trading higher following the receipt of formal minutes from a pre-New Drug Application Type-B Chemistry, Manufacturing, and Controls meeting with the FDA for Tonmya, a treatment for fibromyalgia.
June 20, 2024 | 5:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals shares are trading higher after the company received formal minutes from a pre-NDA Type-B CMC meeting with the FDA for Tonmya, a treatment for fibromyalgia.
The receipt of formal minutes from the FDA meeting is a positive regulatory step for Tonix Pharmaceuticals, indicating progress in the approval process for Tonmya. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100